Management of Metastatic Breast Cancer in Clinical Practice - Retrospective Study
Completed
- Conditions
- Metastatic Breast Cancer
- Registration Number
- NCT01715155
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to evaluate the incidence rate of progression of disease, to describe the diagnostic and clinical management in patients with Metastatic Breast Cancer in the clinical practice in Bulgaria.
- Detailed Description
A Retrospective Cohort Study on Therapeutic Management of Metastatic Breast Cancer in Clinical Practice in Bulgaria
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 171
Inclusion Criteria
- New diagnosis of breast cancer according to ICD-10 with confirmed metastasis
- Confirmed diagnosis between 1st July 2010 and 30th June 2011.
- Female patient managed for her disease at the same setting where final diagnosis of MBC was performed.
Exclusion Criteria
- History of concurrent or other primary malignancies (except curatively resected non-melanoma skin cancer or in situ cervical cancer).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of progression events on a per patient-year-basis Up to 2 years 5 months
- Secondary Outcome Measures
Name Time Method Proportion of patients among study population who have not progressed at 12 and 18 months after they were diagnosed Up to 2 years 5 months Median and mean time interval that elapsed between diagnosis and first objective tumor progression (TTP) event and subsequent events Up to 2 years 5 months Median and mean time from the date of diagnosis to the date of breast cancer progression or death whichever occurred first Up to 2 years 5 months
Trial Locations
- Locations (2)
Research Site
🇧🇬Stara Zagora, Bulgaria
Reaseach Site
🇧🇬Varna, Bulgaria